Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FH-2001 plus Serplulimab in advanced hepatocellular carcinoma and gastric cancer
ChiCTR2400088649Phase 2Not yet recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of FH2001 and serplulimab in hepatocellular carcinoma (HCC) and gastric adenocarcinoma (2 cohorts), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: First-cycle adverse events and serious adverse events. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
FH2001serplulimab
03
Conditions
hepatocellular carcinoma (HCC)gastric adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400088649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088649.